Company research
iBio, Inc.
CIK 1420720Updated Nov 11, 2026
SecurityIBIO · NASDAQ · equity
Name history
iBio, Inc. · through Nov 10, 2026iBioPharma, Inc. · through Aug 14, 2009InB:Biotechnologies, Inc. · through Jul 17, 2008
IBIO price & chart
Loading TradingView…
NASDAQ:IBIO on TradingView ↗About the company
iBio (Nasdaq: IBIO) is a clinical-stage biotechnology developing long-acting antibody therapeutics for obesity, cardiometabolic and cardiopulmonary diseases, cancer, and other hard-to-treat diseases. Combining advanced antibody engineering with AI-driven discovery, iBio is advancing a differentiated pipeline designed to deliver sustained therapeutic effects and address significant unmet medical needs. iBio’s mission is to transform drug discovery, accelerate development timelines, and unlock new possibilities in precision medicine.
In the news
iBio Reports Fiscal Year 2026 Financial Results and Provides Corporate Update ↗
Recent filings
10-Q filing
Results of Operations and Financial Condition
Items 2.02, 9.01
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year · Submission of Matters to a Vote of Security Holders
Items 5.02, 5.03, 5.07, 9.01
4 filing
4 filing
Show 5 more recent filings
4 filing
Regulation FD Disclosure · Other Events
Items 7.01, 8.01, 9.01
Regulation FD Disclosure · Other Events
Items 7.01, 8.01, 9.01
ARS filing
DEF 14A filing
Financials
FY 2026 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2026 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | FY 2026 | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 85,834,000Source | 19,103,000Source | 50,154,000Source | 64,393,000Source | 21,697,000Source | 34,022,000Source | 64,155,000Source | 24,517,000Source | 99,110,000Source | 23,185,000Source | 28,734,000Source | 41,207,000Source |
| Property, Plant and Equipment, NetUSD | 3,310,000Source | 3,284,000Source | 3,726,000Source | 3,447,000Source | 3,391,000Source | 3,890,000Source | 3,210,000Source | 3,511,000Source | 3,086,000Source | 3,163,000Source | 3,632,000Source | 4,219,000Source |
| Intangible Assets, Net (Excluding Goodwill)USD | 1,830,000Source | 6,103,000Source | 5,373,000Source | 4,338,000Source | 6,108,000Source | 5,378,000Source | 6,843,000Source | 5,363,000Source | 1,825,000Source | 6,848,000Source | 5,368,000Source | 5,388,000Source |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 47,631,000Source | 4,959,000Source | 5,302,000Source | 28,672,000Source | 7,015,000Source | 2,788,000Source | 28,111,000Source | 11,038,000Source | 56,395,000Source | 8,582,000Source | 14,210,000Source | 4,301,000Source |
| Inventory, NetUSD | — | — | 0Source | — | — | 0Source | — | — | — | — | 0Source | — |
| Assets, CurrentUSD | 77,251,000Source | 6,060,000Source | 36,139,000Source | 53,368,000Source | 8,285,000Source | 19,699,000Source | 50,772,000Source | 11,705,000Source | 92,221,000Source | 9,721,000Source | 15,672,000Source | 26,259,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 2,454,000Source | 1,101,000Source | 862,000Source | 670,000Source | 1,257,000Source | 894,000Source | 1,140,000Source | 667,000Source | 3,078,000Source | 1,034,000Source | 749,000Source | 664,000Source |
| Operating Lease, Right-of-Use AssetUSD | 1,766,000Source | 2,142,000Source | 2,472,000Source | 1,864,000Source | 2,230,000Source | 2,565,000Source | 1,958,000Source | 2,051,000Source | 1,667,000Source | 2,051,000Source | 2,401,000Source | 2,722,000Source |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 8,297,000Source | 7,722,000Source | 25,291,000Source | 7,833,000Source | 7,802,000Source | 24,825,000Source | 8,116,000Source | 6,763,000Source | 13,397,000Source | 8,305,000Source | 7,410,000Source | 25,826,000Source |
| Stockholders’ equity: | ||||||||||||
| Preferred Stock, Value, IssuedUSD | — | — | — | — | — | — | — | — | — | — | 0Source | — |
| Common Stock, Value, IssuedUSD | 35,000Source | 10,000Source | 9,000Source | 30,000Source | 9,000Source | 30,000Source | 20,000Source | 9,000Source | 56,000Source | 19,000Source | 9,000Source | 20,000Source |
| Retained Earnings (Accumulated Deficit)USD | -354,667,000Source | -327,061,000Source | -306,069,000Source | -346,937,000Source | -322,200,000Source | -302,897,000Source | -337,944,000Source | -317,836,000Source | -365,268,000Source | -332,224,000Source | -313,847,000Source | -288,940,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | -21,000Source | — | — | 10,000Source | — | — | -15,000Source | — | -45,000Source | — | — | — |
| Stockholders' Equity Attributable to ParentUSD | 77,537,000Source | 11,381,000Source | 24,863,000Source | 56,560,000Source | 13,895,000Source | 9,197,000Source | 56,039,000Source | 17,754,000Source | 85,713,000Source | 14,880,000Source | 21,324,000Source | 15,381,000Source |
| Additional Paid in Capital, Common StockUSD | 432,190,000Source | 338,432,000Source | 330,923,000Source | 403,457,000Source | 336,086,000Source | 312,064,000Source | 393,978,000Source | 335,581,000Source | 450,970,000Source | 347,085,000Source | 335,162,000Source | 304,301,000Source |
| Liabilities and EquityUSD | 85,834,000Source | 19,103,000Source | 50,154,000Source | 64,393,000Source | 21,697,000Source | 34,022,000Source | 64,155,000Source | 24,517,000Source | 99,110,000Source | 23,185,000Source | 28,734,000Source | 41,207,000Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 6,504,000Source | 5,397,000Source | 21,426,000Source | 5,901,000Source | 4,709,000Source | 21,553,000Source | 6,048,000Source | 3,469,000Source | 11,745,000Source | 6,106,000Source | 3,840,000Source | 21,582,000Source |
| Operating Lease, Liability, CurrentUSD | 532,000Source | 476,000Source | 424,000Source | 518,000Source | 462,000Source | 412,000Source | 504,000Source | 490,000Source | 546,000Source | 490,000Source | 436,000Source | 389,000Source |
| Accounts Payable, CurrentUSD | 3,035,000Source | 1,477,000Source | 1,228,000Source | 2,654,000Source | 614,000Source | 1,859,000Source | 2,822,000Source | 855,000Source | 4,423,000Source | 2,188,000Source | 358,000Source | 1,849,000Source |
| Operating Lease, Liability, NoncurrentUSD | 1,793,000Source | 2,325,000Source | 2,801,000Source | 1,932,000Source | 2,450,000Source | 2,912,000Source | 2,068,000Source | 2,199,000Source | 1,652,000Source | 2,199,000Source | 2,688,000Source | 3,125,000Source |
| Additional Financial Items | ||||||||||||
| Accrued Liabilities, CurrentUSD | 1,787,000Source | 1,325,000Source | 3,998,000Source | 1,579,000Source | 1,835,000Source | 3,757,000Source | 850,000Source | 1,077,000Source | 5,626,000Source | 1,345,000Source | 2,028,000Source | 4,034,000Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | — | — | 6,431,000Source | — | — | 4,060,000Source | — | — | — | — | — | 7,579,000Source |
| Deferred Revenue, CurrentUSD | — | — | 175,000Source | — | — | 0Source | — | — | — | — | — | 0Source |
| Accounts Receivable, after Allowance for Credit Loss, Current | — | — | — | — | — | — | —Source | — | — | — | — | — |
cash flow · annual statements
| Line item | Q4 2026 | Q4 2025 | Q3 2026 | Q3 2025 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2026 | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | — | — | — | — | — | — | -5,720,000Source | -3,989,000Source | -33,044,000Source | -18,377,000Source | -24,907,000Source | -65,010,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | 323,000Source | 415,000Source | 1,373,000Source | 1,530,000Source | 2,038,000Source | 4,391,000Source |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts ReceivableUSD | — | — | — | — | — | — | 65,000Source | 0Source | 65,000Source | — | — | -1,000,000Source |
| Increase (Decrease) in Accounts PayableUSD | — | — | — | — | — | — | 495,000Source | 497,000Source | 2,223,000Source | 1,831,000Source | -1,491,000Source | -625,000Source |
| Deferred Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | -6,370,000Source | -8,542,000Source | -5,295,000Source | — |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -5,665,000Source | -3,715,000Source | -23,218,000Source | -15,304,000Source | -18,554,000Source | -30,436,000Source |
| Cash flows from investing activities: | ||||||||||||
| Payments to Acquire Businesses, Net of Cash AcquiredUSD | — | — | — | — | — | — | — | — | — | — | — | 692,000Source |
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | -21,493,000Source | 713,000Source | -31,999,000Source | 742,000Source | 906,000Source | 7,009,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | 32,000Source | 0Source | 578,000Source | 16,000Source | 210,000Source | 5,738,000Source |
| Cash flows from financing activities: | ||||||||||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | 46,705,000Source | -162,000Source | 103,048,000Source | 8,929,000Source | 24,494,000Source | 2,301,000Source |
| Proceeds from (Payments for) Other Financing ActivitiesUSD | — | — | — | — | — | — | 50,006,000Source | 0Source | — | 6,246,000Source | — | — |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | 19,547,000Source | -3,164,000Source | 47,831,000Source | -5,633,000Source | 6,846,000Source | -21,093,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | 47,859,000Source | 5,182,000Source | 28,900,000Source | 7,238,000Source | 28,339,000Source | 11,261,000Source | 56,623,000Source | 8,792,000Source | 14,425,000Source | 7,579,000Source |
| Supplemental disclosure of cash flow information: | ||||||||||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | — | — | — | — | — | — | 36,000Source | 57,000Source | 72,000Source | 212,000Source | 749,000Source | 687,000Source |
| Additional Financial Items | ||||||||||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | 377,000Source | 370,000Source | 253,000Source | 475,000Source | 323,000Source | 415,000Source | 1,373,000Source | 1,530,000Source | 1,975,000Source | 2,863,000Source |
| Amortization of Intangible AssetsUSD | — | — | 5,000Source | 5,000Source | 5,000Source | 5,000Source | 5,000Source | 5,000Source | 20,000Source | 20,000Source | 20,000Source | 126,000Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | — | — | — | — | — | — | — | — | — | — | — | 7,579,000Source |
| DepreciationUSD | — | — | — | — | — | — | 123,000Source | 120,000Source | 558,000Source | 484,000Source | 638,000Source | 674,000Source |
| Gain (Loss) on Disposition of Intangible AssetsUSD | — | — | — | — | — | — | — | — | — | — | 1,000,000Source | — |
| Gain (Loss) on Sale of Assets and Asset Impairment ChargesUSD | — | — | — | — | — | — | — | — | — | — | -4,909,000Source | 773,000Source |
| Gain (Loss) on Extinguishment of DebtUSD | — | — | — | — | — | — | — | — | — | — | 808,000Source | — |
| General and Administrative ExpenseUSD | — | — | 5,111,000Source | 2,973,000Source | 5,165,000Source | 2,742,000Source | 2,501,000Source | 2,801,000Source | 10,595,000Source | 10,690,000Source | 11,674,000Source | 19,016,000Source |
| Impairment of Intangible Assets (Excluding Goodwill)USD | — | — | — | — | — | — | — | — | 5,003,000Source | 0Source | 0Source | 565,000Source |
| Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)USD | — | — | — | — | — | — | — | — | 5,003,000Source | — | — | — |
| Income (Loss) from Continuing Operations, Net of Tax, Attributable to ParentUSD | — | — | — | — | — | — | — | — | — | — | — | -29,311,000Source |
| Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling InterestUSD | — | — | — | -4,861,000Source | — | -4,364,000Source | — | -3,989,000Source | — | -18,377,000Source | -15,443,000Source | -29,311,000Source |
| Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling InterestUSD | — | — | — | — | — | — | — | — | — | — | -9,464,000Source | -35,699,000Source |
| Income Tax Expense (Benefit)USD | — | — | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source |
| InterestExpenseNonoperatingUSD | — | — | 22,000Source | 54,000Source | 41,000Source | 57,000Source | 36,000Source | 57,000Source | 53,000Source | 212,000Source | 172,000Source | — |
| Investment Income, InterestUSD | — | — | 657,000Source | 72,000Source | 493,000Source | 112,000Source | 267,000Source | 174,000Source | 2,150,000Source | 437,000Source | 363,000Source | 213,000Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -7,730,000Source | -4,861,000Source | -8,993,000Source | -4,364,000Source | -5,720,000Source | -3,989,000Source | -33,044,000Source | -18,377,000Source | -24,907,000Source | — |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | -7,730,000Source | -4,861,000Source | -8,993,000Source | -4,364,000Source | -5,670,000Source | -3,989,000Source | -33,044,000Source | — | — | -29,311,000Source |
| Nonoperating Income (Expense)USD | — | — | 635,000Source | 18,000Source | 452,000Source | 55,000Source | 231,000Source | 117,000Source | 2,097,000Source | 225,000Source | 1,191,000Source | 32,000Source |
| Operating ExpensesUSD | — | — | 8,365,000Source | 4,879,000Source | 9,445,000Source | 4,619,000Source | 6,051,000Source | 4,106,000Source | 35,241,000Source | 19,002,000Source | 16,859,000Source | 29,343,000Source |
| Proceeds from Issuance of Common StockUSD | — | — | — | — | — | — | 219,000Source | 4,000Source | 3,529,000Source | 3,541,000Source | 25,523,000Source | — |
| Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-saleUSD | — | — | — | — | — | — | — | — | 10,800,000Source | — | — | 4,100,000Source |
| Proceeds from Stock Options ExercisedUSD | — | — | — | — | — | — | — | — | — | 131,000Source | — | 0Source |
income statement · annual statements
| Line item | Q4 2026 | Q4 2025 | Q3 2026 | Q3 2025 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2026 | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total RevenueUSD | — | — | — | — | 0Source | 200,000Source | 100,000Source | 0Source | 100,000Source | 400,000Source | 225,000Source | 0Source |
| Operating Income (Loss)USD | — | — | -8,365,000Source | -4,879,000Source | -9,445,000Source | -4,419,000Source | -5,951,000Source | -4,106,000Source | -35,141,000Source | -18,602,000Source | -16,634,000Source | -29,343,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | — | — | — | — | — | — | — | — | -33,044,000Source | — | — | — |
| Income Tax Expense (Benefit)USD | — | — | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -7,730,000Source | -4,861,000Source | -8,993,000Source | -4,364,000Source | -5,720,000Source | -3,989,000Source | -33,044,000Source | -18,377,000Source | -24,907,000Source | — |
| Earnings Per Share, BasicUSD per share | — | — | -0.06Source | -0.49Source | -0.09Source | -0.48Source | -0.11Source | -0.46Source | -0.32Source | -1.75Source | -6.5Source | -5.31Source |
| Earnings Per Share, DilutedUSD per share | — | — | -0.06Source | -0.49Source | -0.09Source | -0.48Source | -0.11Source | -0.46Source | -0.32Source | -1.75Source | -6.5Source | -5.31Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 119,600,000Source | 9,862,000Source | 99,133,000Source | 9,132,000Source | 52,981,000Source | 8,633,000Source | 104,060,000Source | 10,499,000Source | 3,831,000Source | 12,245,000Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 119,600,000Source | 9,862,000Source | 99,133,000Source | 9,132,000Source | 52,981,000Source | 8,633,000Source | 104,060,000Source | 10,499,000Source | 3,831,000Source | 12,245,000Source |
| Interest Expense (non-operating)USD | — | — | 22,000Source | 54,000Source | 41,000Source | 57,000Source | 36,000Source | 57,000Source | 53,000Source | 212,000Source | 172,000Source | — |
| Additional Financial Items | ||||||||||||
| Amortization of Intangible AssetsUSD | — | — | 5,000Source | 5,000Source | 5,000Source | 5,000Source | 5,000Source | 5,000Source | 20,000Source | 20,000Source | 20,000Source | 126,000Source |
| Current Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 0Source | 0Source | 0Source | 0Source |
| General and Administrative ExpenseUSD | — | — | 5,111,000Source | 2,973,000Source | 5,165,000Source | 2,742,000Source | 2,501,000Source | 2,801,000Source | 10,595,000Source | 10,690,000Source | 11,674,000Source | 19,016,000Source |
| Income (Loss) from Continuing Operations, Net of Tax, Attributable to ParentUSD | — | — | — | — | — | — | — | — | — | — | — | -29,311,000Source |
| Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling InterestUSD | — | — | — | -4,861,000Source | — | -4,364,000Source | — | -3,989,000Source | — | -18,377,000Source | -15,443,000Source | -29,311,000Source |
| Income (Loss) from Continuing Operations, Per Basic ShareUSD per share | — | — | — | -0.49Source | — | -0.48Source | — | -0.46Source | — | -1.75Source | -4.03Source | -2.39Source |
| Income (Loss) from Continuing Operations, Per Diluted ShareUSD per share | — | — | — | -0.49Source | — | -0.48Source | — | -0.46Source | — | -1.75Source | -4.03Source | -2.39Source |
| Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling InterestUSD | — | — | — | — | — | — | — | — | — | — | -9,464,000Source | -35,699,000Source |
| Interest ExpenseUSD | — | — | — | — | — | — | — | — | — | — | — | 83,000Source |
| Investment Income, InterestUSD | — | — | 657,000Source | 72,000Source | 493,000Source | 112,000Source | 267,000Source | 174,000Source | 2,150,000Source | 437,000Source | 363,000Source | 213,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | -7,730,000Source | -4,861,000Source | -8,993,000Source | -4,364,000Source | -5,670,000Source | -3,989,000Source | -33,044,000Source | — | — | -29,311,000Source |
| Nonoperating Income (Expense)USD | — | — | 635,000Source | 18,000Source | 452,000Source | 55,000Source | 231,000Source | 117,000Source | 2,097,000Source | 225,000Source | 1,191,000Source | 32,000Source |
| Operating ExpensesUSD | — | — | 8,365,000Source | 4,879,000Source | 9,445,000Source | 4,619,000Source | 6,051,000Source | 4,106,000Source | 35,241,000Source | 19,002,000Source | 16,859,000Source | 29,343,000Source |
| Research and Development ExpenseUSD | — | — | 3,254,000Source | 1,906,000Source | 4,280,000Source | 1,877,000Source | 3,550,000Source | 1,305,000Source | 19,643,000Source | 8,312,000Source | 5,185,000Source | 10,327,000Source |
Offerings
Registration 333-293864
Registration 333-293085
Filing attachments
ibio-ex99d1.htm · 8-K · 2026-11-10
Exhibit 99.1 iBio Reports Q1 Fiscal Year 2027 Financial Results and Provides Corporate Update Presented additional preclinical data supporting IBIO-610’s potential to drive fat selective weight loss in combination with GLP-1 therapy Completed dosing in the single ascending dose portion of the Phase 1 clinical trial of IBIO-600 Plans to participate in upcoming scientific and investor conferences SAN DIEGO, November 10, 2026 -- iBio, Inc. (NASDAQ: IBIO), a clinical-stage biotechnology company…
Read attachment ↗ibio-ex99d1.htm · 8-K · 2026-10-13
Exhibit 99.1 iBio Highlights Data from a Non-human Primate Study Supporting IBIO-610’s Potential to Preserve Muscle in Combination with GLP-1 Therapy In an eight-week obese NHP study, lean mass made up 6% of weight lost with IBIO-610, an Activin E antibody, plus semaglutide, versus 22% with semaglutide alone iBio expects to start first-in-human trials of IBIO-610 in first half of 2027 SAN DIEGO, Oct. 13, 2026 -- iBio, Inc. (NASDAQ: IBIO), a clinical-stage biotechnology company developing lon…
Read attachment ↗ibio-20260914xex99d1.htm · 8-K · 2026-09-14
EX-99.1 2 ibio-20260914xex99d1.htm EX-99.1 Exhibit 99.1 BREAKTHROUGH ANTIBODIES FOR OBESITY AND CARDIOMETABOLIC DISEASES CORPORATE PRESENTATION • September 2026 ─────────────────────────────────────────── Certain statements in this presentation constitute "forward -looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "conti…
Read attachment ↗ibio-20260731xex4d2.htm · 10-K · 2026-08-28
Exhibit 4.2 DESCRIPTION OF SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED iBio, Inc. (the “Company,” “we,” “us,” and “our”) has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), which is our common stock, par value $0.001 per share (the “common stock”). General The following is a description of the material terms of our common stock. This is a summary only and does no…
Read attachment ↗ibio-20260828xex99d1.htm · 8-K · 2026-08-28
EX-99.1 2 ibio-20260828xex99d1.htm EX-99.1 Exhibit 99.1 iBio Reports Fiscal Year 2026 Financial Results and Provides Corporate Update SAN DIEGO, August 28, 2026 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ: IBIO), a clinical-stage biotechnology company developing long-acting antibody therapeutics for obesity, cardiometabolic and cardiopulmonary diseases, today announced its financial results for the fiscal year ended June 30, 2026, and provided a corporate update on its progress. “Fiscal year 2…
Read attachment ↗ibio-20260722xex99d1.htm · 8-K · 2026-08-04
EX-99.1 3 ibio-20260722xex99d1.htm EX-99.1 Exhibit 99.1 iBio Strengthens Clinical Leadership with Appointment of Endocrinologist Molly Carr as Chief Medical Officer SAN DIEGO, August 4, 2026 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ: IBIO), a clinical-stage biotechnology developing long-acting antibody therapeutics for obesity, cardiometabolic and cardiopulmonary diseases, today announced the appointment of Molly Carr, M.D., as Chief Medical Officer, further strengthening its executive leader…
Read attachment ↗